Octapharma develops and manufactures high-purity human immunoglobulin products for treating immune-mediated diseases and deficiencies.
The immune system plays a key role in numerous conditions. In so-called immune deficiencies, the patient is prone to severe infections due to a lack of naturally occurring protective antibodies (immunoglobulins). Such patients need replacement of the missing immunoglobulins in order to protect them against infections and ensure they can lead a normal life.
Conditions where the immune system is out of balance are generally referred to as immune-mediated diseases, of which auto-immune diseases are a well-known subgroup. Such conditions may lead to various diseases, including bleeding disorders with a reduced number of blood platelets (immune thombocytopenic purpura (ITP)) and inflammatory neurologic conditions such as Guillain-Barré-Syndrome (GBS), chronic demyelinating polyradiculoneuropathy (CIDP) or multiple sclerosis (MS). Many other organ systems can also be a target of an immune-mediated disease.
Immunotherapy treats immune diseases and deficiencies by inducing, enhancing, or suppressing an immune response through immunomodulation or immunoglobulin replacement therapy.
Indications for Octapharma's immunotherapy products
- Primary Immunodeficiency (PID)
- Myeleoma and chronic lymphatic leukaemia (CLL) with severe secondary hypogrammaglobulinaemia
- Immune thrombocytopenic purpura (ITP)
- Kawasaki disease
- Guillain Barre Syndrome (GBS)
- Children with congenital AIDS and recurrent infections
- Allogeneic bone marrow transplantation
Please watch the video to get acquainted with a story from one of the patient.
Octagam® 5% (50 mg/ml) normal intravenous immunoglobulin (IVIG). Liquid, ready-to-use IVIG with a 2 year shelf-life at room temperature (≤ 25°C) storage. Three validated virus reduction steps included in the manufacturing process.
Octagam® 10% (100 mg/ml) normal intravenous immunoglobulin (IVIG). Liquid, ready-to-use IVIG with a 2 year shelf-life at 2-8 °C, including three months at room temperature (≤ 25°C).Three validated virus reduction steps included in the manufacturing process.